切换至 "中华医学电子期刊资源库"
高级检索
中华乳腺病杂志(电子版)

中华乳腺病杂志(电子版) ›› 2015, Vol. 09 ›› Issue (02) : 96 -100. doi: 10.3877/cma. j. issn.1674-0807.2015.02.005

论著

鞘氨醇激酶1 在乳腺癌中的表达及其临床意义
郑晓东1,2, 张彦2, 房慧颖1, 王明浩2, 张毅2,†(), 姜军2,†()   
  1. 1.400030 重庆市肿瘤研究所乳腺外科
    2.400038 重庆,第三军医大学西南医院乳腺外科
  • 收稿日期:2014-12-31 出版日期:2015-04-01
  • 通信作者: 张毅, 姜军
  • 基金资助:
    国家自然科学基金资助项目(81072156)重庆市科技计划项目(cstc2013jcsf10027)重庆市沙坪坝区社会发展领域科技项目(cstc2013jcsf0143)重庆市卫计委科技计划项目(2012-2-505)

Expression of sphingosine kinase 1 in breast cancer and its clinical significance

Xiaodong Zheng1,2, Yan Zhang2, Huiying Fang1, Minghao Wang2, Yi Zhang2,†(), Jun Jiang2,†()   

  1. 1.Department of Breast Surgery,Chongqing Cancer Institute, Chongqing 400030, China
    2.Department of Breast Surgery, Southwest Hospital,Third Military Hospital, Chongqing 400030, China
  • Received:2014-12-31 Published:2015-04-01
  • Corresponding author: Yi Zhang, Jun Jiang
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

郑晓东, 张彦, 房慧颖, 王明浩, 张毅, 姜军. 鞘氨醇激酶1 在乳腺癌中的表达及其临床意义[J/OL]. 中华乳腺病杂志(电子版), 2015, 09(02): 96-100.

Xiaodong Zheng, Yan Zhang, Huiying Fang, Minghao Wang, Yi Zhang, Jun Jiang. Expression of sphingosine kinase 1 in breast cancer and its clinical significance[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2015, 09(02): 96-100.

目的

探讨鞘氨醇激酶1(Sphk1)在乳腺癌中的表达情况及其与临床病理特征及E-钙黏蛋白(E-cadherin)表达的关系。

方法

收集2003 年9 月至2006 年5 月重庆市肿瘤研究所乳腺外科手术切除的乳腺组织标本171 例,包括乳腺纤维腺瘤20 例和浸润性导管癌151 例。 通过免疫组织化学方法检测所有乳腺组织标本中Sphk1 的表达,并分析其与乳腺癌临床病理特征及E-cadherin 表达的关系。 计数资料采用χ2 检验,等级资料采用秩和检验。

结果

Sphk1 在114 例乳腺癌组织中表达阳性,总阳性率为75.50%(114/151),而在乳腺纤维腺瘤组织中均表达阴性(0/20),两组差异有统计学意义(χ2 =45.298,P=0.000)。 Sphk1 表达与乳腺癌淋巴结转移状态(Z=-6.122,P=0.000)、ER(χ2 =4.478,P=0.034)及HER-2 表达(χ2=7.313,P=0.013)有关,而与患者年龄(χ2=2.791,P=0.095)、月经状况(χ2=0.010,P=0.919)、肿瘤直径(Z=-0.249,P=0.804)、PR 表达(χ2=0.740,P=0.390)无关。 在全部浸润性导管癌患者中,E-cadherin 与Sphk1 表达不同的患者其淋巴结转移状态差异有统计学意义(χ2 =17.187, P=0.001)。 E-cadherin (-) 且Sphk1(+)的患者淋巴结阳性率为85.71%(18/21),E-cadherin(+) 且Sphk1(-) 的淋巴结阳性率为30.77%(8/26),两者差异具有统计学意义(χ2 =14.189,P ＜0.008)。

结论

Sphk1 可能在乳腺癌的发生和转移过程中发挥作用,有望作为评估乳腺癌生物学行为的指标。

关键词: 乳腺肿瘤, 肿瘤浸润, E-钙黏蛋白, 鞘氨醇激酶1

Objective

To investigate the expression of sphingosine kinase 1 (Sphk1) and its correlation with clinicopathological characteristics and with E-cadherin expression in breast cancer.

Methods

We collected 171 cases of breast tissue specimens resected in Department of Breast Surgery, Chongqing Cancer Institute from September 2003 to May 2006, including 20 cases of breast fibroadenoma and 151 cases of invasive ductal carcinoma. Immunohistochemistry was used to detect Sphk1 and E-cadherin expression in all breast tissue specimens. The correlations of Sphk1 expression with clinicopathological characteristics and E-cadherin expression were analyzed. The count data were processed using χ2 test, rank data using rank sum test.

Results

Sphk1 was positive in 114 cases of breast cancer (75.50%,114/151), negative in all 20 cases of breast fibroadenoma; the difference was significant (χ2 =45.298,P=0.000); Sphk1 expression was significantly associated with lymph node metastasis(Z=-6.122,P=0.000), ER (χ2 =4.478,P=0.034)and HER-2 expression(χ2 =7.313,P=0.013), not correlated with the patient’ age(χ2 =2.791,P=0.095), menopausal status(χ2 =0.010, P=0.919), tumor diameter (Z=-0.249, P=0.804)or PR expression(χ2=0.740,P=0.390). In all patients with invasive ductal carcinoma, the patients with different E-cadherin and Sphk1 expression status showed a significantdifference in lymph node metastasis (χ2= 17.187, P=0.001). The positive rate of lymph node metastasis was 85.71%(18/21) in the patients with E-cadherin (-) and Sphk1 (+) ,30.77% (8/26) in the patients with Ecadherin (+) and Sphk1 (-), indicating a significant difference (χ2 = 14.189, P＜0.008).

Conclusion

Sphk1 may play an important role in the development and metastasis of breast cancer, which can be a useful indicator to predict the biological behaviors of breast cancer.

Key words: Breast neoplasms, Neoplasm invasiveness, E-cadherin, Sphingosine kinase 1
图1 鞘氨醇激酶1 在乳腺组织中的表达(SP ×200) 注:如图a 所示,鞘氨醇激酶1 在乳腺癌组织中呈阴性表达; 如图b 所示,鞘氨醇激酶1 在乳腺癌组织中呈阳性表达;如图c 所示,鞘氨醇激酶1 在乳腺纤维腺瘤组织中呈阴性表达
图2 E-钙黏蛋白在乳腺组织中的表达(SP ×200) 注:如图a 所示,E-钙黏蛋白在乳腺癌组织中呈阴性表达; 如图b 所示,E-钙黏蛋白在乳腺癌组织中呈阳性表达;如图c 所示,E-钙黏蛋白在乳腺纤维腺瘤组织中呈阳性表达
表1 乳腺浸润性导管癌患者的临床病理特征与Sphk1 表达之间的关系(例)
临床病理特征 Sphk1 检验值 P值
- +
年龄
＞50岁 28 69 2.791 0.095
≤50岁 9 45
月经状态
绝经前 12 38 0.010 0.919
绝经后 25 76
肿瘤直径
≤2 cm 12 39 -0.249a 0.804
＞2～5 cm 22 67
＞5 cm 3 8
淋巴结转移
0枚 31 30 -6.122a 0.000
1～3枚 6 41
4～9枚 0 19
≥10枚 0 24
ER
- 9 50 4.478 0.034
+ 28 64
PR
- 12 46 0.740 0.390
+ 25 68
HER-2
- 35 84 7.313 0.007
+ 2 30
表2 浸润性导管患者Sphk1 与E-cadherin 的联合表达与淋巴结转移的关系
组别 例数 淋巴结状态(例) χ2值 P值
+ -
E-cadherin(+)Sphk1(+) 93 55 38 17.187 0.001
E-cadherin(-)Sphk1(+) 21 18 3
E-cadherin(+)Sphk1(-)a 26 8 18
E-cadherin(-)Sphk1(-)b 11 9 2
[1]
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA Cancer J Clin,2013,63(1):11-30.
[2]
Pappu R, Schwab SR, Cornelissen I, et al. Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate[J]. Science, 2007, 316(5822):295-298.
[3]
Okada T, Kajimoto T, Jahangeer S, et al. Sphingosine kinase/sphingosine 1-phosphate signaling in central nervous system[J]. Cell Signal,2009,21(1):7-13.
[4]
张毅, 周艳, 王姝姝, 等. Sphk1 在乳腺不典型增生及乳腺癌中的表达及意义[J/CD]. 中华乳腺病杂志:电子版,2010,4(2):49-51.
[5]
Lakhani SR,Ellis IO,Schnitt SJ,et al. WHO classification of tumours of the breast[M]. Lyon: IARC Press,2012.
[6]
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual[M].7th ed. New York:Springer,2010:347-376.
[7]
Hammond ME,Hayes DF,Dowsett M,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Clin Oncol,2010,28(16):2784-2795.
[8]
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. J Clin Oncol,2013,31(31):3997-4013.
[9]
Ochiumi T, Tanaka S, Oka S, et al. Clinical significance of angiopoietin-2 expression at the deepest invasive tumor site of advanced colorectal carcinoma [ J]. Int J Oncol, 2004,24 (3):539-547.
[10]
Kohama T, Olivera A, Edsall L, et al. Molecular cloning and functional characterization of murine sphingosine kinase[J]. J Biol Chem,1998,273(37):23722-23728.
[11]
Nava VE, Lacana E, Poulton S, et al. Functional characterization of human sphingosine kinase-1 [J]. FEBS Lett,2000,473(1):81-84.
[12]
Liu H, Sugiura M, Nava VE, et al. Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform[J]. J Biol Chem, 2000, 275(26):19 513-19 520.
[13]
Johnson KR, Johnson KY, Crellin HG, et al.Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue [J]. J Histochem Cytochem,2005,53(9):1159-1166.
[14]
Pyne NJ, Pyne S. Sphingosine 1 phosphate and cancer[J].Nat Rev Cancer,2010,10(7):489-503.
[15]
Guan H, Song L, Cai J, et al. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells[J]. PLoS One,2011,6(5):e19946.
[16]
Nava VE, Hobson JP, Murthy S, et al. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells[J]. Exp Cell Res,2002,281(1):115-127.
[17]
Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, betacatenin and ZEB1 in malignant progression of cancer [J].Cancer Metastasis Rev,2009,28(1-2):151-166.
[18]
Wells A, Yates C, Shepard CR. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas[J]. Clin Exp Metastasis,2008,25(6):621-628.
[19]
Bao M, Chen Z, Xu Y, et al. Sphingosine kinase 1 promotes tumour cell migration and invasion via the S1P/EDG1 axis in hepatocellular carcinoma [J]. Liver Int,2012,32(2):331-338.
[20]
Ruckhäberle E, Rody A, Engels K, et al. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer [J].Breast Cancer Res Treat,2008,112(1):41-52.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号